Skip to main content

Search Videos and More

Showing 145 - 156 of 162 results

Previous| 1... 12 | 13 | 14 |Next

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels?

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

How do you recommend that clinicians directly and immediately apply the results of the CV outcome trials with alirocumab and evolocumab directly to the front lines of medical cardiology practice?

How do you recommend that clinicians directly and immediately apply the results of the CV outcome trials with alirocumab and evolocumab directly to the front lines of medical cardiology practice?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?

Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

Showing 145 - 156 of 162 results

Previous| 1... 12 | 13 | 14 |Next